Evotec Investor Presentation Deck

evotec iPSC alliance in neurodegeneration • Development of novel therapies for a broad range of neuro- degenerative diseases • First programme EVT8683 (elF2b activator) started clinical development 2021 • Phase I read-out expected in 2022 PAGE 19 Proving paradigm shift in iPSC-based discovery BMS alliance Using EVOpanOmics & EVOpanHunter - Development since 2016 2016 evotec & 2017 US$ 5 m - Screening milestone Upfront US$ 45 m • Potential milestones 2017 > US$ 250 m per project • Double-digit royalties ll Bristol Myers Squibb Oct 2018 US$ 6 m - Expansion milestone May 2018 US$ 6 m - Expansion milestone 2018 Sep 2019 US$ 30 m - Extension Dec 2018 US$ 14 m - Lead optimisation payment Sep 2020 US$ 6 m - Expansion milestone 2019 Jan 2020 US$ 6 m - Expansion milestone Sep 2021 US$ 20 m 1st IND Target: elF2b 2020 Dec 2020 US$ 6 m - Expansion milestone Nov 2021 US$ 40 m - Designation of additional programmes 2021 Oct 2021 US$ 9 m - Expansion milestone

View entire presentation